FTC changes premerger notification rules for drug patents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

FTC changes premerger notification rules for drug patents

The FTC has issued final changes to the premerger notification rules governing how pharmaceutical companies must report the acquisition of exclusive patent rights to the FTC and the Antitrust Division of the Department of Justice (DOJ)

Under the Hart-Scott-Rodino (HSR) Act, drug companies must report certain mergers and acquisitions of assets, including patents and exclusive patent licences, over a certain amount to the FTC and DOJ. The current threshold is $70.9 million.

The change will revoke the existing “make, use and sell” standard governing which licences are reportable. Under the current rules, companies are only required to report transfers of patent licences if they allow the buyer to develop, manufacture and sell a product without restriction.

Under the new rules, pharmaceutical companies will have to report transfers falling under the scope of the more stringent “all commercially significant rights” test.

According to the FTC, this will mean that “an exclusive license is substantively the same as buying the patent or part of the patent outright, and carries the same potential anticompetitive effects".

The FTC claims the “make, use and sell” test is “no longer adequate” because some drugs companies were transferring most but not all of the rights under a licence in order to avoid the reporting requirement.

The FTC received four public comments on the rule, including an objection to it from industry organisation Pharmaceutical Research and Manufacturers of America.

The new rules will take effect 30 days after publication in the Federal Register.

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article